check_circleStudy Completed

Dose-escalating Phase I study to define the safety profile, pharmacokinetics, pharmacodynamics and tumor response profile of BAY 43-9006 in combination with oxaliplatin chemotherapy in patients

Trial purpose

Key Participants Requirements

Sex

N/A

Age

32 - 79 Years
  • -

  • -

Trial summary

Enrollment Goal
37
Trial Dates
November 2002 - December 2007
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteer
No

Trial design

Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A